文献速递免疫规划传染病防控与疫情报告

伯氏疏螺旋体BB0172衍生肽疫苗增强莱姆病保护效果

Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease.
PubMed 文献 · Vaccine · 2019-08-03

莱姆病在美国占蜱传疾病70%以上,目前无可用疫苗。本研究将BB0172衍生肽(PepB)与CRM197及破伤风类毒素重链(TTHc)偶联,免疫C3H/HeN小鼠。TTHc:PepB在皮下攻击后保护66%动物,蜱感染模型中细菌负荷降低超70%,血清具杀螺旋体活性。

要点

  • TTHc:PepB偶联疫苗在皮下攻击后保护66%免疫小鼠。
  • 蜱感染模型中,免疫小鼠细菌负荷较对照组降低超70%。
  • 免疫血清具杀伯氏疏螺旋体活性,PepB偶联抗原可作莱姆病预防候选。

核心结论

  • PepB偶联抗原可作为预防莱姆病的替代方案,但需进一步研究抗PepB IgG抗体杀螺旋体机制以推进疫苗开发。

研究设计与样本

  • 研究将PepB与CRM197及TTHc偶联,免疫C3H/HeN小鼠,分别进行皮下攻击(105螺旋体/鼠)和蜱感染模型评估。

主要发现

  • 皮下攻击后,TTHc:PepB构建体保护66%免疫动物。
  • 蜱感染后,免疫小鼠血清具杀螺旋体活性,细菌负荷较对照组降低超70%,无论初次免疫后8周或12周蜱叮咬。

临床怎么用

  • 提示PepB偶联疫苗可能用于莱姆病预防,但尚未进入人体应用,需进一步机制和制剂研究。

局限性

  • 需进一步研究抗PepB IgG抗体在体外和体内杀伯氏疏螺旋体的机制,以推进安全疫苗的制剂和递送开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lyme disease (LD) accounts for over 70% of tick-borne disease reported in the United States. The disease in humans is characterized by skin rash, arthritis, cardiac and neurological signs. Vaccination is the most efficient preventive measure that could be taken to reduce the incidence of the LD worldwide; however, at present no vaccine is available. In this study, evaluation of the Borrelia burgdorferi BB0172-derived peptide (PepB) in conjugated formulations was investigated as a vaccine candidate in murine model of LD. In brief, PepB was conjugated to the Cross-Reacting Material 197 (CRM197) and to Tetanus Toxoid heavy chain (TTHc) molecules, and subsequently used to immunize C3H/HeN mice. Following the challenge with 105 spirochetes/mouse via subcutaneous inoculation, TTHc:PepB construct showed protection in 66% of the immunized animals. Hence, to further evaluate the efficacy of TTHc:PepB, immunized mice were challenged with B. burgdorferi using the tick model of infection. The outcome of this experiment revealed that serum from TTHc:PepB immunized mice was borrelicidal. After tick infection, bacterial burden was significantly reduced (over 70%) in vaccinated animals when compared with the control groups regardless of whether the mice were infested 8 or 12-weeks post-priming. Therefore, we conclude that PepB conjugated antigens can serve as an alternative to prevent LD; nevertheless, further studies will be needed to dissect the mechanisms by which anti-PepB IgG antibodies are able to kill B. burgdorferi in vitro and in vivo to further advance in the development of formulations and delivery alternative to generate a safe anti-LD vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hassan WS, Giaretta PR, Rech R, et al. Enhanced protective efficacy of Borrelia burgdorferi BB0172 derived-peptide based vaccine to control Lyme disease. Vaccine. 2019. PMID: 31387750. doi:10.1016/j.vaccine.2019.07.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。